EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM)

Ragy Saad, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black

Sleep Medicine · 2025

DOI: 10.1016/j.sleep.2025.106587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sleep Medicine, 2025. Verfasst von Ragy Saad und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jazz Pharmaceuticals, 3170 Porter Drive, Palo Alto, CA, 94304, USA. Electronic address: ragysaad@gmail.com. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Idiopathic Hypersomnia, Disorders of Excessive Somnolence. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jazz Pharmaceuticals plc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE/BACKGROUND: Limited research assesses cardiovascular risk in people with idiopathic hypersomnia. This study compared cardiovascular conditions or events among individuals with idiopathic hypersomnia with those among matched non-idiopathic hypersomnia controls. PATIENTS/METHODS: Claims from Merative™ MarketScan® Research Databases (12/2013-2/2020) were analyzed. Eligible individuals with idiopathic hypersomnia were ≥18 years of age upon cohort entry, continuously enrolled for 365 days before and after cohort entry (gaps ≤30 days allowed), and without cataplexy. Individuals with idiopathic hypersomnia entered the cohort upon their earliest medical claim with an idiopathic hypersomnia diagnosis code. Controls were matched 5:1, without replacement, to individuals with idiopathic hypersomnia using demographic characteristics. Odds of prevalent cardiovascular conditions or events during the 2-year assessment period (365 days before and after cohort entry date) were compared using unconditional logistic regression. Results were reported as odds ratios (ORs) with 95 % confidence intervals (CIs). RESULTS: Final cohorts included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. Odds (OR, 95 % CI) of cardiovascular disease (2.26, 2.14-2.38), major adverse cardiovascular event (2.08, 1.89-2.30), stroke (2.07, 1.87-2.29), hypertension diagnosis or antihypertensive use (2.02, 1.93-2.12), heart failure (1.97, 1.76-2.20), atrial fibrillation (1.91, 1.66-2.20), myocardial infarction (1.74, 1.42-2.12), and coronary revascularization (1.58, 1.12-2.17) were higher in individuals with idiopathic hypersomnia than matched controls. CONCLUSIONS: Individuals with idiopathic hypersomnia had higher odds of prevalent cardiovascular conditions or events than matched controls. These results reinforce that clinicians should be aware of patients' cardiovascular risk profiles when selecting idiopathic hypersomnia treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesIdiopathic HypersomniaDisorders of Excessive SomnolenceHumansMaleFemaleMiddle AgedAdultCohort StudiesPrevalence

Stichwörter der Autor:innen

Cardiovascular diseasesCohort studiesHealthcare administrative claimsHypertensionIdiopathic hypersomniaRetrospective studies

Autor:innen und Institutionen

  • Jazz Pharmaceuticals, 3170 Porter Drive, Palo Alto, CA, 94304, USA. Electronic address: ragysaad@gmail.com.
  • Jazz Pharmaceuticals, 3170 Porter Drive, Palo Alto, CA, 94304, USA. Electronic address: plillane@gmail.com.
  • Jazz Pharmaceuticals, 3170 Porter Drive, Palo Alto, CA, 94304, USA. Electronic address: deb.profant@jazzpharma.com.
  • Jazz Pharmaceuticals, 2005 Market Street, Suite 2100, Philadelphia, PA, 19013, USA. Electronic address: doug.fuller@jazzpharma.com.
  • Jazz Pharmaceuticals, 3170 Porter Drive, Palo Alto, CA, 94304, USA. Electronic address: elizabeth.poole@jazzpharma.com.
  • Aetion, 5 Pennsylvania Plaza, New York, NY, 10001, USA. Electronic address: trevormalvord@gmail.com.

Förderung

  • Jazz Pharmaceuticals plc

Zitieren

APA

Saad, R., Lillaney, P., Profant, D. A., Fuller, D. S., Poole, E. M., Alvord, T., Prince, P., Desai, S., Whalen, M., Ni, W., & Black, J. (2025). Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM). Sleep Medicine. https://doi.org/10.1016/j.sleep.2025.106587

Vancouver

Saad R, Lillaney P, Profant DA, Fuller DS, Poole EM, Alvord T, et al. Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM). Sleep Medicine. 2025. doi:10.1016/j.sleep.2025.106587

BibTeX
@article{Saad2025,
  author = {Saad, Ragy and Lillaney, Prasheel and Profant, Deb A and Fuller, Douglas S and Poole, Elizabeth M and Alvord, Trevor and Prince, Patricia and Desai, Shaina and Whalen, Marisa and Ni, Weiyi and Black, Jed},
  title = {Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM)},
  journal = {Sleep Medicine},
  year = {2025},
  doi = {10.1016/j.sleep.2025.106587}
}
Kostenlos starten →